
Opinion|Videos|May 7, 2025
Analyzing Treatment-Refractory Patients
Panelists discuss how managing bronchiectasis exacerbations involves targeted antibiotics based on sputum cultures, augmenting mucus clearance with devices, and considering surgical intervention when medical management fails.
Advertisement
Episodes in this series

Clinical Brief: Approaches to Bronchiectasis Management Beyond Bronchodilators
Main Discussion Topics
- Bronchodilators have a limited role in bronchiectasis management compared with chronic obstructive pulmonary disease and asthma.
- Infection is the primary trigger for exacerbations, making antibiotics a mainstay of treatment.
- Augmented mucus clearance is a crucial complementary approach.
Key Points for Physicians
- Regular sputum cultures help determine appropriate antibiotic choices.
- Combine nebulized hypertonic saline with bronchodilators (albuterol/levalbuterol preferred over anticholinergics).
- Anticholinergics may thicken mucus, potentially making expectoration more difficult.
- Consider airway clearance devices (high-frequency chest wall oscillation, intrapulmonary percussive ventilation) when medical therapies are insufficient.
- Surgical intervention should be considered when infections cannot be controlled medically.
Notable Insights
Patients may be unable to tolerate long-term antibiotics for conditions like MAI complex, making surgery an important consideration in treatment algorithms.
Clinical Significance
A comprehensive approach to bronchiectasis management should prioritize infection control and enhance mucus clearance, with bronchodilators playing a supporting rather than central role.
Advertisement
Related to this article

Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.

Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.

Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.

Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.

“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.

Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.

Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists
3
Twice-Daily Deuruxolitinib Outperformes Once-Daily in Severe AA
4
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
5

